PepGen Ltd (PEPG)
PepGen Ltd. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Its pipeline includes PGN-EDODM1, an EDO peptide-conjugated PMO being evaluated in a Phase 2 trial for myotonic dystrophy type 1, as well as FREEDOM2-DM1, another Phase 2 program targeting the same condition. The company is also conducting FREEDOM-OLE, an open-label extension study. PepGen was founded in 2018 and is based in Boston, Massachusetts. Its common stock is listed on the NASDAQ under the ticker PEPG.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PEPG
|
$3.05
|
36.0% Upside
|
Undervalued
|
$10.25
|
357.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-2.0x
|
1.2x
|
—
|
152.2 M
|
39.889 M
|
9.8%
|
52.1%
|
-0.1
|
—
|
100.1%
|
